Cytokinetics (CYTK) is now covered by Wells Fargo & Company. They set an "overweight" rating and a $95.00 price target on the stock.
Cytokinetics (CYTK) was upgraded by Barclays PLC to "strong-buy".
Cytokinetics to Participate in the 25th Annual Needham Virtual Healthcare Conference
Cytokinetics (CYTK) had its price target raised by Barclays PLC from $87.00 to $95.00. They now have an "overweight" rating on the stock.
Cytokinetics MYQORZO Approval And CEO Sale Put Valuation In Focus [Yahoo! Finance]